866-997-4948 (US-Canada Toll Free)

ADHD Therapeutics Market to 2018 - New Diagnostic Parameters for Adult ADHD Offer Hope for Higher Rates of Treatment

Published By :

GBI Research

Published Date : 2013-04-15

Category :

Pharmaceutical

No. of Pages : N/A

Product Synopsis


ADHD Therapeutics Market to 2018 - New Diagnostic Parameters for Adult ADHD Offer Hope for Higher Rates of Treatment

GBI Research, the leading business intelligence provider, has released its latest research: “ADHD Therapeutics Market to 2018 - New Diagnostic Parameters for Adult ADHD Offer Hope for Higher Rates of Treatment”. The report provides insights into the up-and-coming trends of the ADHD market in seven major markets: the US, the top five European countries (France, Germany, Italy, Spain and the UK) and Japan. 

The report includes market forecasts to 2019, detailed pipeline analysis, in-depth profiling of major products and details of recent industry deals. The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Research’s team of industry experts. 

The ADHD therapeutics market is expected to show strong growth in Spain and Japan, with Compound Annual Growth Rates (CAGRs) of 8% and 15% respectively. However, the total revenues of these markets are still expected to be much lower than the largest market, the US, which is expected to reach $6,260m by 2018. This is due to the much higher diagnosis rates for both adults and children with ADHD in the US.

Scope

  • Current and future treatment and diagnosis trends for ADHAD
  • Market forecasts for ADHD across seven major markets
  • Analysis of the developmental pipelines for ADHD
  • Information on recent industry deals
Reasons to Buy

  • Understand how the ADHD market has developed and is continuing to develop within the featured markets
  • Predict which products are likely to be most successful in the future
  • Gain an understanding of the possible market available for specific products

Table Of Content

1 Table of Contents
1.1 List of Figures
1.2 List of Tables

2 Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market to 2018 – Executive Summary

3 ADHD Therapeutics Market to 2018 – Introduction
3.1 Etiology and Pathophysiology
3.1.1 Genetic Influences
3.1.2 Environmental Influences
3.1.3 Pathophysiology
3.2 Epidemiology
3.2.1 Child/Adult Subpopulations
3.2.2 Male/Female
3.3 Diagnosis
3.3.1 DSM-IV Criteria for ADHD
3.3.1.1 DSM-V Revision
3.3.2 ICD-10 Criteria for Hyperkinetic Disorder
3.3.3 Diagnostic Rating Scales
3.3.4 Issues with Diagnosis
3.3.5 Co-Morbid Disorders
3.4 Treatment and Management Options
3.4.1 Pharmacologic Treatment
3.5 Drivers and Barriers for ADHD Therapeutics Market
3.5.1 Drivers
3.5.1.1 High Prevalence of ADHD
3.5.1.2 Need for Effective Non-Stimulant Therapies
3.5.2 Barriers
3.5.2.1 Increasingly Competitive Market
3.5.2.2 Social Factors
3.5.2.3 High Level of Co-Morbidity
3.6 Report Guidance

4 ADHD Therapeutics: Market Characterization by Geography
4.1 All Major Markets
4.1.1 Market Size – All Major Markets
4.1.2 Market Forecast – All Major Markets
4.1.3 Annual Cost of Therapy – Average of All Major Markets
4.2 The US
4.2.1 Market Size – The US
4.2.2 Market Forecast - The US
4.2.3 Annual Cost of Therapy – The US
4.3 Top 5 Countries of Europe
4.3.1 Market Size – France
4.3.2 Market Forecast – France
4.3.3 Annual Cost of Therapy – France
4.3.4 Market Size – Germany
4.3.5 Market Forecast – Germany
4.3.6 Annual Cost of Therapy – Germany
4.3.7 Market Size – Italy
4.3.8 Market Forecast – Italy
4.3.9 Annual Cost of Therapy – Italy
4.3.10 Market Size – Spain
4.3.11 Market Forecast – Spain
4.3.12 Annual Cost of Therapy – Spain
4.3.13 Market Size – The UK
4.3.14 Market Forecast – The UK
4.3.15 Average Annual Cost of Therapy – The UK
4.4 Japan
4.4.1 Market Size – Japan
4.4.2 Market Forecast – Japan
4.4.3 Annual Cost of Therapy – Japan

5 ADHD Therapeutics Market to 2018 – Competitive Landscape
5.1 Overview of Major Marketed Products in the ADHD market
5.1.1 Adderall XR (mixed amphetamine salt)
5.1.1.1 Overview
5.1.1.2 Efficacy
5.1.1.3 Safety
5.1.2 Daytrana (methylphenidate transdermal patch)
5.1.2.1 Overview
5.1.2.2 Efficacy
5.1.2.3 Safety
5.1.3 Concerta (methylphenidate hydrochloride)
5.1.3.1 Overview
5.1.3.2 Efficacy
5.1.3.3 Safety
5.1.4 Intuniv (guanfacine)
5.1.4.1 Overview
5.1.4.2 Efficacy
5.1.4.3 Safety
5.1.5 Strattera (atomoxetine hydrochloride)
5.1.5.1 Overview
5.1.5.2 Efficacy
5.1.5.3 Safety
5.1.6 Vyvanse (lisdexamfetamine dimesylate)
5.1.6.1 Overview
5.1.6.2 Efficacy
5.1.6.3 Safety
5.1.7 Kapvay (clonidine hydrochloride)
5.1.7.1 Overview
5.1.7.2 Efficacy
5.1.7.3 Safety
5.1.8 Focalin XR (dexmethylphenidate hydrochloride)
5.1.8.1 Overview
5.1.8.2 Efficacy
5.1.8.3 Safety
5.1.9 Generic products

6 ADHDTherapeutics Market to 2018 – Product Pipeline Analysis
6.1 Introduction
6.2 ADHD Therapeutics Pipeline – Pipeline by Phases of Development
6.3 Trends in the ADHD Therapeutic Pipeline

7 ADHD Therapeutics Market to 2018 – Strategic Consolidations
7.1 Overview
7.1.1 Deals by Deal Type
7.1.2 Deals by Year
7.1.3 Deals by Geography
7.1.4 Deals by Value
7.2 M&A Landscape
7.2.1 M&A Deals by Deal Type
7.2.2 M&A Deals by Year
7.2.3 M&A Deals by Geography
7.2.4 M&A Deals by Deal Value
7.2.5 Sanofi-Aventis Merger, 2004
7.3 R&D Licensing Agreements
7.3.1 Deals by Year
7.3.2 Deals by Geography
7.3.3 Deals by Deals Value
7.3.4 Targacept and AstraZeneca Agreement, 2009
7.4 Co-Development Agreements
7.4.1 Deals by Year
7.4.2 Deals by Geography
7.4.3 Deals by Deal Value
7.4.4 Shire and New River Co-Development Deal, 2005

8 Appendix
8.1 Abbreviations
8.2 Research Methodology
8.2.1 Coverage
8.2.2 Secondary Research
8.2.3 Primary Research
8.2.4 Market Size by Geography
8.3 Geographical Landscape
8.4 Pipeline Analysis
8.5 Competitive Landscape
8.5.1 Expert Panel Validation
8.6 Contact Us
8.7 Disclaimer
8.8 Sources
8.9 Disclaimer

List of Tables

Table 1: DSM-IV criteria for attention deficit hyperactivity disorder
Table 2: CD-10 criteria for hyperkinetic disorders
Table 3: ADHD Therapeutics, Marketed Products Overview, 2012
Table 4: ADHD Therapeutics, Pre-Clinical Pipeline, 2012
Table 5: ADHD Therapeutics, Phase I Pipeline, 2012
Table 6: ADHD Therapeutics, Phase II Pipeline, 2012
Table 7: ADHD Therapeutics, Phase III 2012
Table 8: ADHD Therapeutics – Pipeline Molecules by Mechanism of Action, 2012
Table 9: M&A Deals by Deal Value

List of Figures

Figure 1: ADHD All Major Markets Market Size ($m) 2006-2011
Figure 2: ADHD All Major Markets Market Forecast ($m) 2012-2018
Figure 3: ADHD Annual Cost of Therapy All Markets ($) 2006-2018
Figure 4: ADHD Market Size US ($m) 2006-2011
Figure 5: ADHD Market Forecast US ($m) 2012-2018
Figure 6: ADHD Annual Cost of Therapy The US ($) 2006-2018
Figure 7: ADHD Market Size France ($m) 2006-2011
Figure 8: ADHD Market Forecast France ($m) 2012-2018
Figure 9: ADHD Annual Cost of Therapy France ($) 2006-2018
Figure 10: ADHD Market Size Germany ($m) 2006-2011
Figure 11: ADHD Market Forecast Germany ($m) 2012-2018
Figure 12: ADHD Annual Cost of Therapy Germany ($) 2006-2018
Figure 13: ADHD Market Size Italy ($m) 2006-2011
Figure 14: ADHD Market Forecast Italy ($m) 2012-2018
Figure 15: ADHD Annual Cost of Therapy Italy ($) 2006-2018
Figure 16: ADHD Market Size Spain ($m) 2006-2011
Figure 17: ADHD Market Forecast Spain ($m) 2012-2018
Figure 18: ADHD Annual Cost of Therapy Spain ($) 2006-2018
Figure 19: ADHD Market Size UK ($m) 2006-2011
Figure 20: ADHD Market Forecast UK ($m) 2012-2018
Figure 21: ADHD Annual Cost of Therapy The UK ($) 2006-2018
Figure 22: ADHD Market Size Japan ($m) 2006-2011
Figure 23: ADHD Market Forecast Japan ($m) 2012-2018
Figure 24: ADHD Therapeutics – Pipeline by Phase of Development, 2012
Figure 25: ADHD Therapeutics – Pipeline Molecules by Mechanism of Action, 2012
Figure 26: ADHD Therapeutics – Pipeline by Program Type, 2012
Figure 27: ADHD Therapeutics – Inactive/Discontinued Pipeline Molecules by Target, 2012
Figure 28: Total Deals by Deal Type
Figure 29: Total Deals by Year
Figure 30: Total Deals by Geography
Figure 31: Total Deals by Deal Value
Figure 32: M&A Deals by Deal Type
Figure 33: M&A Deals by Year
Figure 34: M&A Deals by Geography
Figure 35: R&D Licensing Agreements Deals by Year
Figure 36: R&D Licensing Agreements Deals by Geography
Figure 37: R&D Licensing Agreements Deals by DealsValue
Figure 38: Co-Development Agreements Deals by Year
Figure 39: Co-Development Agreements Deals by Geography
Figure 40: Co-Development Agreements Deals by Deal Value
Figure 41: GBI Research Market Forecasting Model

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *

Upcoming Reports

  • Printing And Writing Papers Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019

    By - Transparency

    Printing and writing papers are used for newspapers, books, magazines, stationeries, commercial printing and digital printing among others. On the basis of product type, the printing and writing papers market is divided into coated mechanical, uncoated mechanical, coated free-sheet and uncoated free-sheet. Among the product segment, only uncoated mechanical has shown growth and is anticipated to follow similar trend over forecast period.  The market for printing and writing papers was mainly driven by increasing demand from tissue and packaging products. The demand has...

  • Lip Cancer Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2014 - 2020

    By - Transparency

    Lip cancer is a type of oral cancer that begins in the squamous cells, lining the lips and the oral cavity. Symptoms of lip cancer include soreness, lumps or pale colored ulcers in the mouth that are usually painless at first but may become painful with disease progression. On early diagnosis, this type of cancer can be cured either by surgery and/or radiation therapy. In cases of advanced stages, chemotherapy and targeted therapies may also be used. Emergency treatment is recommended in cases where cancer has spread and is known to interfere with the function of a vital organ. Factors...

  • Printed And Flexible Sensors Market - Global Industry Size, Market Share, Trends, Analysis, And Forecasts 2012 - 2018

    By - Transparency

    The printed and flexible sensor market represents recent trends in the development of devices that extend primary sensory abilities of humans. Such sensors are standalone devices that will enhance one’s comfort while measuring different physical parameters. Printed and flexible sensors offer distinct advantages over non-printed sensors like low cost, small size, flexibility, efficiency, and built on variety of substrates. Such sensors are adding intelligence to industrial processes, packaging, toys, etc. Printed and flexible sensors are creating new markets by offering...